Invesco NASDAQ Next Gen 100 ETF (QQQJ)
- Previous Close
27.23 - Open
27.33 - Bid 27.41 x 400
- Ask 27.49 x 400
- Day's Range
27.24 - 27.52 - 52 Week Range
22.66 - 29.29 - Volume
82,164 - Avg. Volume
132,215 - Net Assets 712.47M
- NAV 27.43
- PE Ratio (TTM) 20.92
- Yield 0.69%
- YTD Daily Total Return 1.95%
- Beta (5Y Monthly) 1.09
- Expense Ratio (net) 0.15%
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, Nasdaq, Inc. compiles, maintains and calculates the underlying index, which is comprised of securities of the next generation of Nasdaq-listed non-financial companies; that is, the largest 100 Nasdaq-listed companies outside of the NASDAQ-100 Index® (the “NASDAQ-100”) based on market capitalization.
Invesco
Fund Family
Mid-Cap Growth
Fund Category
712.47M
Net Assets
2020-10-13
Inception Date
Performance Overview: QQQJ
Trailing returns as of 4/26/2024. Category is Mid-Cap Growth.
People Also Watch
Holdings: QQQJ
Top 10 Holdings (19.22% of Total Assets)
Sector Weightings
Recent News: QQQJ
Research Reports: QQQJ
Daily – Vickers Top Buyers & Sellers for 04/19/2024
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Analyst Report: CRISPR Therapeutics AG
Crispr Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
RatingPrice TargetAnalyst Report: Block, Inc.
Founded in 2009, Block provides payment services to merchants, along with related services. The company also launched Cash App, a person-to-person payment network. In 2023, Square's payment volume was a little over $200 million.
RatingPrice TargetAnalyst Report: Block Inc.
Block, which changed its name from Square in late 2021, is a technology platform company that provides payment and point-of-sale solutions to merchants worldwide. While changing its name, Block retained many of its well-known product titles, including its Square terminals. The company provides merchants with hardware for sales and payment solutions, along with software that converts iPads to payment terminals. Payments can be made on Square terminals via a tap, dip, or swipe, or through the company's Block Cash electronic tender. Block also provides CashApp, which allows consumers to send, spend, and store money on an app. Block processes transactions in the U.S. and internationally.
RatingPrice Target